Table 1 Clinicopathological characteristics of patients with breast cancer.
From: The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy
Characteristics | Luminal A (n = 11) | Luminal B (n = 15) | Her2 (n = 2) | Triple Negative (n = 5) | HD (n = 10) |
|---|---|---|---|---|---|
Age (years) | |||||
< 40 | 1 (9.1) | 0 (0) | 0 (0) | 2 (40.0) | 5 (50.0) |
40–49 | 1 (9.1) | 3 (20.0) | 1 (50.0) | 1 (20.0) | 5 (50.0) |
50–65 | 4 (36.3) | 5 (33.3) | 0 (0) | 2 (40.0) | 0 (0) |
> 65 | 5 (45.4) | 7 (46.7) | 1 (50.0) | 0 (0) | 0 (0) |
Lymph nodes | |||||
Negative | 9 (81.8) | 8 (53.3) | 1 (50.0) | 3 (60.0) | |
Positive | 2 (18.1) | 7 (46.7) | 1 (50.0) | 2 (40.0) | |
TNM stage(AJCC) | |||||
I | 0 (0) | 1 (6.7) | 0 (0) | 1 (20.0) | |
II | 7 (63.6) | 11 (73.3) | 0 (0) | 2 (40.0) | |
III | 4 (36.3) | 3 (20.0) | 2 (100) | 2 (40.0) | |
IV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Ki67 | |||||
< 20% | 10 (90.0) | 0 (0) | 1 (50.0) | 1 (20.0) | |
> 20% | 1 (0.09) | 15 (100) | 1 (50.0) | 4 (40.0) | |
Neoadjuvant chemotherapy | |||||
AC | 0(0) | 2 (13.3) | 1 (50.0) | 1 (20.0) | |
AC + TX | 8 (72.7) | 9 (60.0) | 1 (50.0) | 2 (40.0) | |
Non therapy | 3 (27.2) | 4 (26.7) | 0 (0) | 2 (40.0) | |
Pathological response | |||||
pCR | 0(0) | 5 (33.3) | 1 (50.0) | 3 (60.0) | |
Non-pCR | 11 (100) | 10 (66.6) | 1 (50.0) | 2 (40.0) | |
